Focus on HIV Care

Back to articles

Poorer Drug Responses, Hepatotoxicity with Hepatitis C Coinfection

KEY POINT

Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at higher risk for liver toxicities when treated with protease inhibitors (PIs), according to a recent study. In addition, coinfected patients with liver toxicities have poorer clinical outcomes than those patients who do not have drug-related hepatotoxicity. However, poster presentations at a recent antiretroviral conference demonstrate key differences between coinfected patients and those who only have HIV, so the observed distinctions may not be linked solely to antiretroviral medications.

SOURCES

Aceti A et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C infection. J Acquir Immune Defic Syndr. 2002;29:41–8.

Sabin CA et al. Poorer immunological response to HAART in HCV+ve individuals coinfected with hepatitis C virus (HCV). Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Wash.

Fuster D et al. Factors associated with liver fibrosis in HIV-1/HCV coinfected patients on antiretroviral therapy. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Wash.